Skip to main content

Neurology

RSS  

Articles

  • Post-Traumatic Headaches: Common and Complicated

    The brain’s ability to modulate pain influences the development and persistence of post-traumatic headache (PTH). Functional magnetic resonance imaging (fMRI) studies in people with PTH show higher pain-induced brain activation in specific regions, such as the postcentral gyrus, superior temporal gyrus, and ventral striatum, as compared to healthy controls. Over 16 weeks of observation, progressive normalization in pain-induced brain activation was seen in the PTH group with headache improvement, with persistently elevated activation in the non-improvement PTH group.

  • 24-Hour Activity Rhythms and Amyloid-β Deposition in the Brain

    This study of dementia-free adults found that greater variability of the 24-hour activity rhythm (greater during the daytime as well as during sleep time) with fragmentation of sleep predicted increased deposition of amyloid-β (Aβ), especially in apolipoprotein E 4 (APOE4) carriers.

  • Post-Traumatic Headaches: Common and Complicated

    The brain’s ability to modulate pain influences the development and persistence of post-traumatic headache (PTH). Functional magnetic resonance imaging (fMRI) studies in people with PTH show higher pain-induced brain activation in specific regions, such as the postcentral gyrus, superior temporal gyrus, and ventral striatum, as compared to healthy controls. Over 16 weeks of observation, progressive normalization in pain-induced brain activation was seen in the PTH group with headache improvement, with persistently elevated activation in the non-improvement PTH group.

  • Epilepsy in Frontotemporal Dementia

    This Finnish case-control study explores the relationship between frontotemporal dementia (FTD) and epilepsy, revealing that individuals with FTD have a higher prevalence of epilepsy compared to those with Alzheimer’s disease (AD) and healthy controls. The findings suggest that epilepsy may precede FTD diagnosis and is more common in FTD than previously recognized, highlighting the need for broader research and clinical awareness of this comorbidity.

  • Use of IV Tenecteplase Prior to Thrombectomy in Stroke

    In patients with acute ischemic stroke arriving at a thrombectomy-ready hospital within 4.5 hours of stroke onset, the combination of treatment with intravenous tenecteplase followed by mechanical thrombectomy resulted in superior outcomes compared to thrombectomy alone.

  • Rituximab to Prevent Relapse in Anti-NMDAR Antibody-Mediated Encephalitis

    This long-term follow-up study of 67 patients with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis demonstrated that initial treatment with rituximab was associated with a longer time before a relapse occurred.

  • Treating Small Vessel PCNSV with Cyclophosphamide

    In this single-center study, 26 adults with biopsy-confirmed small vessel primary central nervous system vasculitis (PCNSV) were followed for a median of 49 months. Patients receiving early treatment with cyclophosphamide within three months of immunosuppression initiation achieved remission faster than those receiving conservative initial treatment with corticosteroids, either as monotherapy or with azathioprine, mycophenolate, or methotrexate. Retrospective design, treatment selection bias, small sample size, and clinicopathologic heterogeneity limit therapeutic inferences and highlight the need for prospective trials.

  • Evaluation and Management of Diplopia in the Emergency Department

    Diplopia is an uncommon presenting complaint in the emergency department that can be associated with life- and vision-threatening diagnoses. Comprehensive management typically requires an interdisciplinary team, often including both ophthalmology and neurology. This article provides emergency physicians with an organized resource that they can quickly reference for guidance on the assessment, management, and disposition of diplopia patients.

  • Nipocalimab-aahu Injection (Imaavy)

    The U.S. Food and Drug Administration has approved a neonatal Fc-receptor (FcRn) blocker for the treatment of generalized myasthenia gravis. Nipocalimab-aahu is a recombinant human immunoglobulin G1 lambda monoclonal antibody directed at FcRn with high affinity and selectivity.

  • TIA Is Associated with Accelerated Cognitive Decline

    The study investigators looked at data from a prospective study of 30,239 Black and white community-dwelling persons aged 45 years or older with cognitive evaluations over the phone every other year until 2022. The researchers documented patients who had transient ischemic attack (TIA) or stroke, and demonstrated that persons who had TIA had a cognitive decline trajectory similar to those patients who had a definite diagnosis of stroke.